Madrigal Pharmaceuticals
MDGL
487.72
-8.73
-1.76%
Madrigal Pharmaceuticals
US · MDGL
#1355 by market cap
Listed 2016
487.72
-8.73
-1.76%
Live - 5344 symbols - heartbeat 415s ago
· 2026-10-08 07:10
Pre-market
498.89
+2.29%
After-hours
487.72
0.00%
- Market cap
- 11.27B
- P/E (TTM)i
- -34.86
- P/Bi
- 21.52
- EPSi
- -12.85
- Div yieldi
- 0.00%
- 52W posi
- 43%
Reader sentiment
Are you bullish or bearish on MDGL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 8.83, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +432.05% YoY
Margins
- Gross margin
- 94.14%
- Operating margin
- -31.31%
- Net margin
- -30.08%
Key ratios & quality
- Enterprise valuei
- 10.63B
- Altman Z-Scorei
- 8.83
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 180.13M | 958.40M |
| Gross profit | -- | -- | -- | -- | 0 | 0 | 173.90M | 902.26M |
| Selling & admin expenses | 15.29M | 22.65M | 21.86M | 37.32M | 48.13M | 108.15M | 435.06M | 813.83M |
| Research & development | 25.39M | 72.32M | 184.81M | 205.16M | 245.44M | 272.35M | 236.72M | 388.53M |
| Operating profit | -40.68M | -94.97M | -206.67M | -242.48M | -293.57M | -380.50M | -497.88M | -300.10M |
| Pretax profit | -32.81M | -83.95M | -202.24M | -241.85M | -295.35M | -373.63M | -465.89M | -288.28M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -32.81M | -83.95M | -202.24M | -241.85M | -295.35M | -373.63M | -465.89M | -288.28M |
| Basic EPS | -2 | -5 | -13 | -15 | -17 | -20 | -22 | -13 |
| Diluted EPS | -2.22 | -5.45 | -13.09 | -14.63 | -17.23 | -19.99 | -21.90 | -12.85 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 137.25M | 212.80M | 287.27M | 321.08M | 311.34M | 364.25M |
| Gross profit | 132.74M | 203.74M | 269.15M | 296.64M | 284.49M | 324.25M |
| Selling & admin expenses | 167.88M | 196.86M | 209.12M | 239.98M | 268.52M | 289.38M |
| Research & development | 44.17M | 54.08M | 174.00M | 116.27M | 108.69M | 91.18M |
| Operating profit | -79.31M | -47.20M | -113.98M | -59.61M | -92.72M | -56.31M |
| Pretax profit | -73.24M | -42.28M | -114.19M | -58.58M | -94.39M | -57.94M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -73.24M | -42.28M | -114.19M | -58.58M | -94.39M | -57.94M |
| Basic EPS | -3 | -2 | -5 | -3 | -3 | -2 |
| Diluted EPS | -2.61 | -1.50 | -5.08 | -2.57 | -3.25 | -1.99 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 485.20M | 440.20M | 285.16M | 271.68M | 361.37M | 637.28M | 1.03B | 1.25B |
| Cash & ST investments | 483.72M | 439.05M | 284.15M | 270.35M | 358.77M | 634.13M | 926.25M | 983.56M |
| Inventory | -- | -- | -- | -- | -- | 0 | 34.07M | 74.84M |
| Total assets | 485.43M | 442.06M | 287.00M | 273.33M | 362.57M | 640.55M | 1.04B | 1.26B |
| Total current liabilities | 8.44M | 25.13M | 46.56M | 76.84M | 115.89M | 118.55M | 169.28M | 310.29M |
| Short-term debt | -- | 315.00K | 318.00K | 410.00K | 602.00K | 527.00K | 983.00K | 1.02M |
| Long-term debt | -- | -- | -- | -- | 49.29M | 115.48M | 117.57M | 339.88M |
| Total liabilities | 8,444,000.00 | 25,491,000.00 | 47,025,000.00 | 77,225,000.00 | 165,183,000.00 | 235,214,000.00 | 287,864,000.00 | 656,900,000.00 |
| Total equity | 476.98M | 416.57M | 239.97M | 196.11M | 197.39M | 405.33M | 754.38M | 602.69M |
| Retained earnings | -139.27M | -223.22M | -425.46M | -667.31M | -962.66M | -1.34B | -1.80B | -2.09B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 987.98M | 1.00B | 1.35B | 1.25B | 1.18B | 1.20B |
| Cash & ST investments | 843.07M | 797.02M | 1.11B | 983.56M | 812.77M | 838.75M |
| Inventory | 55.24M | 63.50M | 69.32M | 74.84M | 112.07M | 99.39M |
| Total assets | 996.63M | 1.02B | 1.36B | 1.26B | 1.23B | 1.24B |
| Total current liabilities | 167.24M | 196.50M | 391.41M | 310.29M | 338.26M | 374.20M |
| Short-term debt | 1.02M | 1.05M | 1.08M | 1.02M | 1.70M | 1.03M |
| Long-term debt | 118.01M | 118.38M | 339.75M | 339.88M | 340.33M | 340.79M |
| Total liabilities | 285,992,000.00 | 319,403,000.00 | 736,725,000.00 | 656,900,000.00 | 683,873,000.00 | 720,921,000.00 |
| Total equity | 710.64M | 695.98M | 625.73M | 602.69M | 543.45M | 523.72M |
| Retained earnings | -1.88B | -1.92B | -2.03B | -2.09B | -2.18B | -2.24B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -25.51M | -41.62M | -157.56M | -183.92M | -224.86M | -324.23M | -455.57M | -189.55M |
| Depreciation & amortization | 96.00K | 112.00K | 471.00K | 405.00K | 467.00K | 527.00K | 1.10M | 1.51M |
| Free cash flow | -25.53M | -41.80M | -157.90M | -184.13M | -225.07M | -325.71M | -462.03M | -193.02M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 311.83M | 0 | 4.42M | 170.21M | 255.38M | 260.19M | 397.49M | 0 |
| Ending cash balance | 57.38M | 46.70M | 54.00M | 36.27M | 331.55M | 99.92M | 105.02M | 203.78M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -88.89M | -47.05M | 79.85M | -133.46M | -167.44M | 23.33M |
| Depreciation & amortization | 379.00K | 377.00K | 358.00K | 392.00K | 386.00K | 381.00K |
| Free cash flow | -88.89M | -47.05M | 75.99M | -133.07M | -171.28M | 19.08M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 8.64M | -- | -- | 0 | 2.33M | -- |
| Ending cash balance | 188.65M | 191.19M | 300.69M | 203.78M | 232.19M | 292.88M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -9.95 | -18.79 | -61.61 | -110.92 | -150.12 | -123.98 | -80.35 | -42.49 |
| ROA %i | -9.68 | -18.10 | -55.48 | -86.32 | -92.89 | -74.49 | -55.37 | -25.05 |
| ROIC %i | -12.28 | -21.23 | -62.79 | -110.68 | -132.18 | -98.86 | -71.30 | -33.26 |
| 5-year avg ROE %i | -- | -- | -- | -45.95 | -70.28 | -93.08 | -105.39 | -101.57 |
| EBIT margin %i | -- | -- | -- | -- | -- | -- | -250.49 | -27.75 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 57.46 | 17.52 | 6.13 | 3.54 | 3.12 | 5.38 | 6.10 | 4.01 |
| Quick ratioi | 57.29 | 17.47 | 6.10 | 3.52 | 3.10 | 5.35 | 5.79 | 3.60 |
| Debt / assetsi | 0.00 | 0.15 | 0.27 | 0.29 | 13.76 | 18.30 | 11.47 | 27.60 |
| LT debt / equityi | -- | 0.09 | 0.20 | 0.20 | 24.97 | 28.78 | 15.72 | 57.51 |
| Interest coveragei | -- | -- | -- | -- | -73.51 | -28.39 | -30.76 | -11.92 |
| Revenue CAGR (3Y) %i | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -50.16 | -36.30 | -41.22 | -42.49 | -49.35 | -53.31 |
| ROA %i | -37.67 | -26.66 | -23.74 | -25.05 | -27.83 | -28.77 |
| ROIC %i | -47.27 | -34.52 | -33.25 | -33.26 | -37.05 | -38.87 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -118.93 | -52.01 | -36.67 | -27.75 | -24.95 | -22.87 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 5.91 | 5.11 | 3.44 | 4.01 | 3.50 | 3.20 |
| Quick ratioi | 5.41 | 4.46 | 3.12 | 3.60 | 2.96 | 2.76 |
| Debt / assetsi | 12.02 | 12.21 | 25.42 | 27.60 | 28.30 | 27.94 |
| LT debt / equityi | 16.71 | 17.66 | 55.19 | 57.51 | 63.60 | 66.20 |
| Interest coveragei | -26.71 | -19.52 | -15.51 | -11.92 | -10.53 | -9.32 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Product revenue, net100.00%
Quote time 2026-10-08 07:10:38 · For reference only, not investment advice and not tailored to your situation.